Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
Children saw improvements in their atopic dermatitis with tapinarof regardless of their atopic comorbidities, according to ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...
Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...
SAN FRANCISCO, Nov. 19, 2025 /PRNewswire/ -- ixlayer, the leading cloud-based platform powering end-to-end direct-to-patient (DTP) healthcare, today announced the launch of SkinLink.us--a platform ...
6don MSN
Kymera Therapeutics stock soars 46%. Why investors are excited about its anti-inflammatory drug.
Researchers are probing its efficacy in patients with Type 2 inflammatory diseases, which are triggered by an overactive ...
Zacks Investment Research on MSN
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...
Learn more about whether Immunocore Holdings plc or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ ...
Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback